Crossroads of Signaling Pathways

  • Stefania Staibano


As studies on PC progression continue to uncover a growing number of crosstalks and co-occurrences of mutations and epigenetic alterations, new drugs are getting approved bringing significant changes in the treatment paradigm of these tumors.

This chapter recapitulates the best known examples of molecular interactions potentially targetable to achieve these therapeutic evolutionary changes, to allow a better control of PC which, in 2012 alone, has still killed more than 28,000 men, in USA (Siegel et al, CA Cancer J Clin, 62:10–29, 2012; El-Amm, Aragon-Ching, Ther Adv Med Oncol, 5(1):25–40, 2013).


Prostate Cancer Vascular Endothelial Growth Factor Prostate Tumor Prostate Epithelial Cell Ku80 Expression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Akhurst RJ, Derynck R (2001) TGF-beta signaling in cancer – a double-edged sword. Trends Cell Biol 11:S44–S51PubMedGoogle Scholar
  2. An WG et al (1998) Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 392(6674):405–408PubMedGoogle Scholar
  3. Anastasiadis AG, Bemis DL, Stisser BC, Salomon L, Ghafar MA, Buttyan R (2003) Tumor cell hypoxia and the hypoxia-response signaling system as a target for prostate cancer therapy. Curr Drug Target 4:191–196Google Scholar
  4. Attar RM, Takimoto CH, Gottardis MM (2009) Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res 15:3251–3255PubMedGoogle Scholar
  5. Banham AH, Boddy J, Launchbury R, Han C, Turley H, Malone PR, Harris AL, Fox SB (2007) Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia. Prostate 67:1091–1098PubMedGoogle Scholar
  6. Boddy JL, Fox SB, Han C, Campo L, Turley H, Kanga S, Malone PR, Harris AL (2005) The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin Cancer Res 11:7658–7663PubMedGoogle Scholar
  7. Bonaccorsi L, Marchiani S, Muratori M, Forti G, Baldi E (2004) Gefitinib (‘IRESSA’, ZD1839) inhibits EGFinduced invasion in prostate cancer cells by suppressing PI3 K/AKT activation. J Cancer Res Clin Oncol 130:604–614PubMedGoogle Scholar
  8. Burfeind P, Chernicky CL, Rininsland F, Ilan J (1996) Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. PNAS 93:7263–7268PubMedGoogle Scholar
  9. Byrne RL, Leung H, Neal DE (1996) Peptide growth factors in the prostate as mediators of stromal epithelial interaction. Br J Urol 77:627–633PubMedGoogle Scholar
  10. Camps JL, Chang SM, Hsu TC, Freeman MR, Hong SJ, Zhau HE, von Eschenbach AC, Chung LW (1990) Fibroblastmediated acceleration of human epithelial tumor growth in vivo. PNAS 87:75–79PubMedGoogle Scholar
  11. Cardillo MR, Petrangeli E, Perracchio L, Salvatori L, Ravenna L, Di Silverio F (2000) Transforming growth factor-beta expression in prostate neoplasia. Anal Quant Cytol Histol 22:1–10PubMedGoogle Scholar
  12. Castellano G, Malaponte G, Mazzarino MC, Figini M, Marchese F, Gangemi P et al (2008) Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Clin Cancer Res 14:7470–7480PubMedGoogle Scholar
  13. Chang IY, Youn CK, Kim HB et al (2005) Oncogenic H-Ras upregulates expression of Ku80 to protect cells from gamma-ray irradiation in NIH3T3 cells. Cancer Res 65:6811–6819PubMedGoogle Scholar
  14. Chen L, Elahi A, Pow-Sang J, Lazarus P, Park J (2003) Association between polymorphism of human oxoguanine glycosylase 1 and risk of prostate cancer. J Urol 170:2471–2474PubMedGoogle Scholar
  15. Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang SM, Harari PM (2005) Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 62:223–229PubMedGoogle Scholar
  16. Chipuk JE, Cornelius SC, Pultz NJ, Jorgensen JS, Bonham MJ, Kim SJ, Danielpour D (2002) The androgen receptor represses transforming growth factor-beta signaling through interaction with Smad3. J Biol Chem 277:1240–1248PubMedGoogle Scholar
  17. Cho-Chung YS (1989) Site-selective 8-chloro- cyclic adenosine 3′,5′-monophosphate as a biologic modulator of cancer: restoration of normal control mechanisms. J Natl Cancer Inst 81:982–987PubMedGoogle Scholar
  18. Cho-Chung YS (1990) Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: new approaches to therapy. Cancer Res 50:7093–7100PubMedGoogle Scholar
  19. Choudhury A, Cuddihy A, Bristow RG (2006) Radiation and new molecular agents part I: targeting ATM-ATR checkpoints, DNA repair, and the proteasome. Semin Radiat Oncol 16:51–58PubMedGoogle Scholar
  20. Coffey RJ Jr, Shipley GD, Moses HL (1986) Production of transforming growth factors by human colon cancer lines. Cancer Res 46:1164–1169PubMedGoogle Scholar
  21. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867PubMedGoogle Scholar
  22. Craft N, Shostak Y, Carey M, Sawyers CL (1999) A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5:280–285PubMedGoogle Scholar
  23. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H (1994) Androgen receptor activation in prostatic tumor cell lines by insulinlike growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54:5474–5478PubMedGoogle Scholar
  24. Cunha GR, Donjacour AA (1989) Mesenchymal–epithelial interactions in the growth and development of the prostate. Cancer Treat Res 46:159–175PubMedGoogle Scholar
  25. Cunha GR, Hayward SW, Dahiya R, Foster BA (1996) Smooth muscle–epithelial interactions in normal and neoplastic prostatic development. Acta Anat 155:63–72PubMedGoogle Scholar
  26. Dayyani F, Gallick GE, Logothetis CJ, Corn PG (2011) Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 103(22):1665–1675PubMedGoogle Scholar
  27. Delongchamps NB, Peyromaure M, Dinh-Xuan AT (2006) Role of vascular endothelial growth factor in prostate cancer. Urology 68:244–248PubMedGoogle Scholar
  28. Derynck R, Zhang YE (2003) Smad-dependent and Smadindependent pathways in TGF-beta family signalling. Nature 425:577–584PubMedGoogle Scholar
  29. Di Lorenzo G, Tortora G, D’Armiento FP, De Rosa G, Staibano S, Autorino R, D’Armiento M, De Laurentiis M, De Placido S, Catalano G et al (2002) Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 8:3438–3444PubMedGoogle Scholar
  30. Di Lorenzo G, Autorino R, D’Armiento FP, Mignogna C, De Laurentiis M, De Sio M et al (2004) Expression of proto-oncogene c-kit in high risk prostate cancer. Eur J Surg Oncol 30:987–992PubMedGoogle Scholar
  31. Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, Stubbs H, McDermott U, Settleman J, Kwak EL, Clark JW, Isakoff SJ, Sequist LV, Engelman JA, Lynch TJ, Haber DA, Louis DN, Ellisen LW, Borger DR, Iafrate AJ (2010) Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med 2(5):146–158PubMedGoogle Scholar
  32. Dittmann K, Mayer C, Fehrenbacher B et al (2005a) Radiationinduced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 280:31182–31189PubMedGoogle Scholar
  33. Dittmann K, Mayer C, Rodemann HP (2005b) Inhibition of radiationinduced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol 76:157–161PubMedGoogle Scholar
  34. El-Amm J, Aragon-Ching JB (2013) The changing landscape in the treatment of metastatic castration resistant prostate cancer. Ther Adv Med Oncol 5(1):25–40PubMedGoogle Scholar
  35. Ellis L, Hammers H, Pili R (2009) Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 280(2):145–153. ReviewPubMedGoogle Scholar
  36. Feldser D et al (1999) Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res 59(16):3915–3918PubMedGoogle Scholar
  37. Festuccia C, Muzi P, Millimaggi D, Biordi L, Gravina GL, Speca S, Angelucci A, Dolo V, Vicentini C, Bologna M (2005) Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTENnegative prostate cancer cell lines. Endocr-Relat Cancer 12:983–998PubMedGoogle Scholar
  38. Fong GH, Rossant J, Gertsenstein M, Breitman ML (1995) Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376:66–70PubMedGoogle Scholar
  39. Gerdes MJ, Dang TD, Larsen M, Rowley DR (1998) Transforming growth factor-beta1 induces nuclear to cytoplasmic distribution of androgen receptor and inhibits androgen response in prostate smooth muscle cells. Endocrinology 139:3569–3577PubMedGoogle Scholar
  40. Gerdes MJ, Larsen M, Dang TD, Ressler SJ, Tuxhorn JA, Rowley DR (2004) Regulation of rat prostate stromal cell myodifferentiation by androgen and TGF-beta1. Prostate 58:299–307PubMedGoogle Scholar
  41. Gonzalez-Herrera IG, Prado-Lourenco L, Pileur F, Conte C, Morin A, Cabon F, Prats H, Vagner S, Bayard F, Audigier S et al (2006) Testosterone regulates FGF-2 expression during testis maturation by an IRES-dependent translational mechanism. FASEB J 20:476–478PubMedGoogle Scholar
  42. Heinlein CA, Chang C (2004) Androgen receptor in prostate cancer. Endocr Rev 25:276–308PubMedGoogle Scholar
  43. Henshall SM, Quinn DI, Lee CS, Head DR, Golovsky D, Brenner PC, Delprado W, Stricker PD, Grygiel JJ, Sutherland RL (2001) Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res 61:423–427PubMedGoogle Scholar
  44. Horii K, Suzuki Y, Kondo Y, Akimoto M, Nishimura T, Yamabe Y et al (2007) Androgen-dependent gene expression of prostatespecific antigen is enhanced synergistically by hypoxia in human prostate cancer cells. Mol Cancer Res 5:383–391PubMedGoogle Scholar
  45. Ivan M, Kaelin WG Jr (2001) The von Hippel–Lindau tumor suppressor protein. Curr Opin Genet Dev 11(1):27–34PubMedGoogle Scholar
  46. Johansson A, Rudolfsson S, Hammarsten P, Halin S, Pietras K, Jones J et al (2010) Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am J Pathol 177:1031–1041PubMedGoogle Scholar
  47. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415–428PubMedGoogle Scholar
  48. Kang JH et al (2008) CCAAT box is required for the induction of human thrombospondin-1 gene by trichostatin A. J Cell Biochem 104(4):1192–1203PubMedGoogle Scholar
  49. Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2(10):727–739PubMedGoogle Scholar
  50. Kim MS et al (2001) Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7(4):437–443PubMedGoogle Scholar
  51. Kwon HJ et al (2002) Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int J Cancer 97(3):290–296PubMedGoogle Scholar
  52. Leong KG, Wang BE, Johnson L, Gao WQ (2008) Generation of a prostate from a single adult stem cell. Nature 456:804–808PubMedGoogle Scholar
  53. Leotoing L, Manin M, Monte D, Baron S, Communal Y, Lours C, Veyssiere G, Morel L, Beaudoin C (2007) Crosstalk between androgen receptor and epidermal growth factor receptor-signalling pathways: a molecular switch for epithelial cell differentiation. J Mol Endocrinol 39:151–162PubMedGoogle Scholar
  54. Liu Y, Majumder S, McCall W, Sartor CI, Mohler JL, Gregory CW, Earp HS, Whang YE (2005) Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res 65:3404–3409PubMedGoogle Scholar
  55. Liu T et al (2006) Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev 32(3):157–165PubMedGoogle Scholar
  56. Ma BB, Bristow RG, Kim J, Siu LL (2003) Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. J Clin Oncol 21:2760–2776PubMedGoogle Scholar
  57. Mabjeesh NJ, Amir S (2007) Hypoxia-inducible factor (HIF) in human tumorigenesis. Histol Histopathol 22(5):559–572PubMedGoogle Scholar
  58. Mantalaris A, Panoskaltsis N, Sakai Y et al (2001) Localization of androgen receptor expression in human bone marrow. J Pathol 193:361–366PubMedGoogle Scholar
  59. Marignol L, Coffey M, Lawler M, Hollywood D (2008) Hypoxia in prostate cancer: a powerful shield against tumour destruction? Cancer Treat Rev 34(4):313–327PubMedGoogle Scholar
  60. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL (2004) HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6:517–527PubMedGoogle Scholar
  61. Memarzadeh S, Xin L, Mulholland DJ, Mansukhani A, Wu H, Teitell MA, Witte ON (2007) Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell 12:572–585PubMedGoogle Scholar
  62. Meng X, Riordan NH (2006) Cancer is a functional repair tissue. Med Hypotheses 66:486–490PubMedGoogle Scholar
  63. Murr R (2010) Interplay between different epigenetic modifications and mechanisms. Adv Genet 70:101–141PubMedGoogle Scholar
  64. Nakano K, Fukabori Y, Itoh N, Lu W, Kan M, McKeehan WL, Yamanaka H (1999) Androgen-stimulated human prostate epithelial growth mediated by stromal-derived fibroblast growth factor-10. Endocr J 46:405–413PubMedGoogle Scholar
  65. Niu Y, Xu Y, Zhang J, Bai J, Yang H, Ma T (2001) Proliferation and differentiation of prostatic stromal cells. BJU Int 87:386–393PubMedGoogle Scholar
  66. Niu Y, Chang TM, Yeh S, Ma WL, Wang YZ, Chang C (2010) Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails. Oncogene 29:3593–3604PubMedGoogle Scholar
  67. Norris AM, Woodruff RD, D’Agostino RB Jr, Clodfelter JE, Scarpinato KD (2007) Elevated levels of the mismatch repair protein PMS2 are associated with prostate cancer. Prostate 67:214–225PubMedGoogle Scholar
  68. Ohlson N, Bergh A, Stattin P, Wikstrom P (2007) Castrationinduced epithelial cell death in human prostate tissue is related to locally reduced IGF-1 levels. Prostate 67:32–40PubMedGoogle Scholar
  69. Orio F Jr, Terouanne B, Georget V, Lumbroso S, Avances C, Siatka C, Sultan C (2002) Potential action of IGF-1 and EGF on androgen receptor nuclear transfer and transactivation in normal and cancer human prostate cell lines. Mol Cell Endocrinol 198:105–114PubMedGoogle Scholar
  70. Ornitz DM, Itoh N (2001) Fibroblast growth factors. Genome Biol 2(3):REVIEWS3005. Epub 2001 Mar 9. Review. PubMed PMID: 11276432; PubMed Central PMCID: PMC138918Google Scholar
  71. Peterziel H, Mink S, Schonert A, Becker M, Klocker H, Cato AC (1999) Rapid signalling by androgen receptor in prostate cancer cells. Oncogene 18:6322–6329PubMedGoogle Scholar
  72. Pittoni P, Piconese S, Tripodo C, Colombo MP (2010) Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors. Oncogene 30:757–769PubMedGoogle Scholar
  73. Pittoni P, Tripodo C, Piconese S, Mauri G, Parenza M, Rigoni A, Sangaletti S, Colombo MP (2011) Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. Cancer Res 71(18):5987–5997PubMedGoogle Scholar
  74. Pollak M, Beamer W, Zhang JC (1998) Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev 17:383–390PubMedGoogle Scholar
  75. Prtilo A, Leach FS, Markwalder R et al (2005) Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer. J Urol 174:1814–1818, discussion p. 18PubMedGoogle Scholar
  76. Qian DZ et al (2004) The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 64(18):6626–6634PubMedGoogle Scholar
  77. Richard DE et al (1999) P42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J Biol Chem 274(46):32631–32637PubMedGoogle Scholar
  78. Rinaldo F, Li J, Wang E, Muders M, Datta K (2007) RalA regulates vascular endothelial growth factor-C (VEGF-C) synthesis in prostate cancer cells during androgen ablation. Oncogene 26:1731–1738PubMedGoogle Scholar
  79. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH et al (1986) Transforming growth factor type beta: rapid induction offibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. PNAS 83:4167–4171PubMedGoogle Scholar
  80. Rochester MA, Riedemann J, Hellawell GO, Brewster SF, Macaulay VM (2005) Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther 12:90–100PubMedGoogle Scholar
  81. Rosini P, Bonaccorsi L, Baldi E, Chiasserini C, Forti G, De Chiara G, Lucibello M, Mongiat M, Iozzo RV, Garaci E et al (2002) Androgen receptor expression induces FGF2, FGF-binding protein production, and FGF2 release in prostate carcinoma cells: role of FGF2 in growth, survival, and androgen receptor down-modulation. Prostate 53:310–321PubMedGoogle Scholar
  82. Rossig L et al (2002) Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ Res 91(9):837–844PubMedGoogle Scholar
  83. Russell PJ, Bennett S, Stricker P (1998) Growth factor involvement in progression of prostate cancer. Clin Chem 44:705–723PubMedGoogle Scholar
  84. Rybicki BA, Conti DV, Moreira A, Cicek M, Casey G, Witte JS (2004) DNA repair gene XRCC1 and XPD polymorphisms and risk of prostate cancer. Cancer Epidemiol Biomark Prev 13:23–29Google Scholar
  85. Salm SN, Koikawa Y, Ogilvie V, Tsujimura A, Coetzee S, Moscatelli D, Moore E, Lepor H, Shapiro E, Sun TT et al (2000) Generation of active TGF-beta by prostatic cell cocultures using novel basal and luminal prostatic epithelial cell lines. J Cell Physiol 184:70–79PubMedGoogle Scholar
  86. Sar M, Lubahn DB, French FS, Wilson EM (1990) Immunohistochemical localization of the androgen receptor in rat and human tissues. Endocrinology 127:3180–3186PubMedGoogle Scholar
  87. Saric T, Shain SA (1998) Androgen regulation of prostate cancer cell FGF-1, FGF-2, and FGF-8: preferential downregulation of FGF-2 transcripts. Growth Fact 16:69–87Google Scholar
  88. Sarwar M, Persson JL (2011) The protein kinase a (PKA) intracellular pathway and androgen receptor: a novel mechanism underlying the castration-resistant and metastatic prostate cancer. J Cancer Sci Ther S5:003Google Scholar
  89. Sasakawa Y et al (2003) Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochem Pharmacol 66(6):897–906PubMedGoogle Scholar
  90. Semenza GL (1998) Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr Opin Genet Dev 8(5):588–594PubMedGoogle Scholar
  91. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(10):29Google Scholar
  92. Sporn MB, Roberts AB (1992) Transforming growth factorbeta: recent progress and new challenges. J Cell Biol 119:1017–1021PubMedGoogle Scholar
  93. Stiehl DP et al (2002) Normoxic induction of the hypoxia-inducible factor 1alpha by insulin and interleukin-1beta involves the phosphatidylinositol 3-kinase pathway. FEBS Lett 512(1–3):157–162PubMedGoogle Scholar
  94. Sun X, Chen C, Vessella RL, Dong JT (2006) Microsatellite instability and mismatch repair target gene mutations in cell lines and xenografts of prostate cancer. Prostate 66:660–666PubMedGoogle Scholar
  95. Wang H, Song K, Sponseller TL, Danielpour D (2005) Novel function of androgen receptor-associated protein 55/Hic-5 as a negative regulator of Smad3 signaling. J Biol Chem 280:5154–5162PubMedGoogle Scholar
  96. Wang X, Yin L, Rao P, Stein R, Harsch KM, Lee Z, Heston WD (2007) Targeted treatment of prostate cancer. J Cell Biochem 102:571–579PubMedGoogle Scholar
  97. Weidemann A, Johnson RS (2008) Biology of HIF-1alpha. Cell Death Differ 15(4):621–627PubMedGoogle Scholar
  98. Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, Adami HO, Trichopoulos D (1998) Insulin-like growth factor 1 and prostate cancer risk: a population-based, case–control study. J Natl Cancer Inst 90:911–915PubMedGoogle Scholar
  99. Wu Y, Zhao W, Zhao J, Pan J, Wu Q, Zhang Y, Bauman WA, Cardozo CP (2007) Identification of androgen response elements in the insulin-like growth factor I upstream promoter. Endocrinology 148:2984–2993PubMedGoogle Scholar
  100. Xu J, Zheng SL, Turner A et al (2002) Associations between hOGG1 sequence variants and prostate cancer susceptibility. Cancer Res 62:2253–2257PubMedGoogle Scholar
  101. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C (1999) From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. PNAS 96:5458–5463PubMedGoogle Scholar
  102. Yeh CC, Lee C, Dahiya R (2001) DNA mismatch repair enzyme activity and gene expression in prostate cancer. Biochem Biophys Res Commun 285:409–413PubMedGoogle Scholar
  103. Yoshizawa A, Ogikubo S (2006) IGF binding protein-5 synthesis is regulated by testosterone through transcriptional mechanisms in androgen responsive cells. Endocr J 53:811–818PubMedGoogle Scholar
  104. Yuan TC, Veeramani S, Lin MF (2007) Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer 14:531–547PubMedGoogle Scholar
  105. Zavadil J, Bottinger EP (2005) TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 24:5764–5774PubMedGoogle Scholar
  106. Zelzer E et al (1998) Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. EMBO J 17(17):5085–5094PubMedGoogle Scholar
  107. Zhou J, Schmid T, Schnitzer S, Brüne B (2006) Tumor hypoxia and cancer progression. Cancer Lett 237(1):10–21PubMedGoogle Scholar
  108. Zhu B, Kyprianou N (2005) Transforming growth factor beta and prostate cancer. Cancer Treat Res 126:157–173PubMedGoogle Scholar
  109. Zhu ML, Kyprianou N (2008) Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer 15(4):841–849PubMedGoogle Scholar
  110. Zhu B, Fukada K, Zhu H, Kyprianou N (2006) Prohibitin and cofilin are intracellular effectors of transforming growth factor beta signaling in human prostate cancer cells. Cancer Res 66:8640–8647PubMedGoogle Scholar
  111. Zundel W et al (2000) Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14(4):391–396PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  1. 1.Department of Advanced Biomedical Sciences, Pathology Section, Faculty of Medicine and SurgeryUniversity of Naples “Federico II”NaplesItaly

Personalised recommendations